

DAFTAR PUSTAKA

- Alberti, G, 2005. Introduction to the metabolic syndrome. *European Heart Journal Supplements*, 7 (Supplement D), D3-D5.
- Alberti, K., Eckertl, R., Grundy, S., 2009. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*, 120:1640-1645.
- Adnyana, I.W.L. & Sutanegara, I.N.D., 2004. Obesitas dan Resistensi Insulin. Dalam *Majalah Penyakit Dalam Udayana* 5(3): 235-45.
- Al-Tukmagi *et al.*, 2012. *Adjuvant use of Angiotensin Receptor Blockers with Metformin in Patients with Polycystic Ovary Syndrome*. [online] Available at: <http://pharmacologia.com/abstract.php?doi=pharmacologia.2012.15.19> [Accessed 30 Oct. 2014].
- Amy Barreras, C. (2003). Angiotensin II receptor blockers. *Proceedings (Baylor University Medical Center)*, [online] 16(1), p.123. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1200815/> [Accessed 30 Oct. 2014].
- Boivin, A., Brochu, G., Marceau, S., Marceau, P., Hould, F., Tchernof, A., 2007. Regional Difference in Adipose Tissue Metabolism in Obese Men. *Metabolism*, 56(3): 533-540.
- Bouchez, C. (2014). *Can Stress Cause Weight Gain*. [online] Webmd.com. Available at: <http://www.webmd.com/diet/features/can-stress-cause-weight-gain> [Accessed 24 Dec. 2014].
- Burnier, M., 2001. Angiotensin II Type 1 Receptor Blockers. *Circulation*, 103(6), pp.904-912. Available at:

<http://circ.ahajournals.org/cgi/doi/10.1161/01.CIR.103.6.904> [Accessed October 30, 2014].

- Despres, J., Lemieux, I., Prud'home, D., 2001. Treatment of Obesity: Need to Focus on High Risk Abdominally Obese Patient. *British Medical Journal*, 322: 716-20.
- Diken, H., Kelle, M., Tomer, C., Denuz, B., Baylan, Y., Permet, A., 2001. Effects of Cigarette Smoking on Blood Antioxidant Status in Short-Term and Long-Term Smokers. *Turkish Journal of Medical Sciences*, (31):553-557.
- Drugbank.ca, (2014). *DrugBank: Valsartan (DB00177)*. [online] Available at: <http://www.drugbank.ca/drugs/DB00177> [Accessed 30 Oct. 2014]
- Druglib.com, (2014). *Diovan (Valsartan) - Description and Clinical Pharmacology*. [online] Available at: http://www.druglib.com/druginfo/diovan/description_pharmacology/ [Accessed 30 Oct. 2014].
- Eckel, R.H., Alberti, K.G., Grundy, S.M., Zimmet, P.Z., 2010. The Metabolic Syndrome. *Lancet*, 375(9710):181-183.
- Eisai Inc, 2012. The pathophysiology of obesity: Causes and consequences.
- Ford, S., Roach, S. & Roach, S. (2010). *Roach's introductory clinical pharmacology*. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health.
- Fox, C., Massaro, J., Hoffmann, U., Pou, K., Maurovich-Horvat, P., Liu, C., Vasan, R., Murabito, J., Meigs, J., Cupples, L., D'Agostino, R. & O'Donnell, C., 2007. Abdominal Visceral and Subcutaneous Adipose Tissue Compartments: Association With Metabolic Risk Factors in the Framingham Heart Study. *Circulation*, 116(1), pp.39-48.

- Fujimoto, W., Jablonski, K., Bray, G., 2007. Body size and shape changes and the risk of diabetes in the diabetes prevention program. *Diabetes*, 56:1680-5.
- Gesta, S., Tseng, Y & Kahn, C., (2007). Developmental Origin of Fat: Tracking Obesity to Its Source. *Cell*, 131(2), pp.242-256.
- Glaser Pediatric Research Network Obesity Study Group, 2009. Intra-peritoneal fat and insulin resistance in obese adolescent. *Obesity*, 18(2), pp.402-409.
- Goodman, L., Gilman, A. & Brunton, L. (2008). *Goodman & Gilman's manual of pharmacology and therapeutics*. New York: McGraw-Hill Medical.
- Goossens, G., Blaak, E., Saris, W. & van Baak, M. (2004). Angiotensin II-Induced Effects on Adipose and Skeletal Muscle Tissue Blood Flow and Lipolysis in Normal-Weight and Obese Subjects. *The Journal of Clinical Endocrinology & Metabolism*, 89(6), pp.2690-2696.
- Goossens, G., Moors, C., Van der Zijl, N., Venteclef, N., Alili, R., Jocken, J., Essers, Y., Cleutjens, J., Clément, K., Diamant, M. & Blaak, E. (2012). Valsartan Improves Adipose Tissue Function in Humans with Impaired Glucose Metabolism: A Randomized Placebo-Controlled Double-Blind Trial. *PLoS ONE*, 7(6), p.e39930.
- Grandy, S., Fox, K., Hardy, E., 2013. Association of weight loss and medication adherence among adults with type 2 diabetes mellitus: SHIELD (Study to help improve early evaluation and management of risk factors leading to diabetes). *Current Therapeutic Research* 75: 77-82.
- Grundy, S. (2004). Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. *Circulation*, 109(3), pp.433-438.
- Grundy, S. (2005). Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood

Institute Scientific Statement: Executive Summary.
Circulation, 112(17), pp.e285-e290.

Grundy, S. (2008). Metabolic Syndrome Pandemic.
Arteriosclerosis, Thrombosis, and Vascular Biology, 28(4), pp.629-636.

Han, T., Van, I., Seidell, J., 1995. Waist Circumference Action Levels in the Identification of Cardiovascular Risk Factor Prevalence Study in a Random Sample. *BMJ*, 311: 1401-15.

Hall, J. & Guyton, A. (2006). *Guyton dan Hall Buku Ajar Fisiologi Kedokteran*, edisi 11. EGC Medical Publisher, Jakarta.

Huang, P.L., 2009. A comprehensive definition for metabolic syndrome. *Disease models & mechanisms*, 2(5-6), pp.231-7. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2675814&tool=pmcentrez&rendertype=abstract> [Accessed October 15, 2014].

Iwashita, M., Nakatsu, Y., Sakoda, H., Fujishiro, M., Kushiya, A., Fukushima, T., Kumamoto, S., Shinjo, T., Kamata, H., Nishimura, F. & Asano, T. (2013). Valsartan restores inflammatory response by macrophages in adipose and hepatic tissues of LPS-infused mice. *Adipocyte*, 2(1), pp.28-32.

Jo, J., Gavrilova, O., Pack, S., Jou, W., Mullen, S., Sumner, A., Cushman, S. & Periwai, V. (2009). Hypertrophy and/or Hyperplasia: Dynamics of Adipose Tissue Growth. *PLoS Computational Biology*, 5(3), p.e1000324.

Kasper, D. & Harrison, T. (2005). *Harrison's principles of internal medicine*. New York: McGraw-Hill, Medical Pub. Division.

Katzung, B., Masters, S. & Trevor, A. (2009). *Basic & clinical pharmacology*. New York: McGraw-Hill Medical.

Kern, P.A., Di Gregorio, G.B., Lu, T., 2003. Adiponectin Expression from Human Adipose Tissue. *Diabetes* 52: 1779-85.

- Klein, S., et al., 2007. Waist Circumference and cardiometabolic risk: a consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. *The American Journal of Clinical Nutrition*, 85:1197-202.
- KM, F., 2015. Daily stress, coping, and dietary restraint in binge eating. - PubMed - NCBI. [online] Ncbi.nlm.nih.gov. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15282690> [Accessed 1 Jan. 2015].
- Kurtz, T. & Pravenec, M. (2004). Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. *Journal of Hypertension*, 22(12), pp.2253-2261.
- Lau, T., Carlsson, P.O. & Leung, P.S., 2004. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. *Diabetologia*, 47(2), pp.240-8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14722647> [Accessed October 30, 2014].
- Lean, M. (2000). Pathophysiology of Obesity. *Proceedings Of The Nutrition Society.*, 59(03), pp.331-336.
- Lean, M.E., Han, T.S., Bush, H., Anderson, A.S., Bradby, H., Williams, R., 2001. Ethnic Differences In Anthropometric And Lifestyle Measures Related To Coronary Heart Disease Risk Between South Asian, Italian And General Population British Women Living In The West Of Scotland. *International Journal of Obesity*, 25(12):1800-5.
- Leung, P. (2001). Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas. *Journal of Molecular Endocrinology*, 26(3), pp.155-164.

- Maeda, N., Shimomura, I., Kishida, K., 2002. Diet-induced Insulin Resistance in Mice Lacking Adiponectin/ ARCP30. *Diabetologia* 28: 412-9.
- Matsuzawa, Y., Funahashi, T. & Nakamura, T., 2011. The Concept of Metabolic Syndrome: Contribution of Visceral Fat Accumulation and Its Molecular Mechanism. *Journal of Atherosclerosis and Thrombosis*, 18(8), pp.629-639. Available at: <http://joi.jlc.jst.go.jp/JST.JSTAGE/jat/7922?from=CrossRef>.
- McNamara, J., Jenner, J., Li, Z., Wilson, P. & Schaefer, E. (1992). Change in LDL particle size is associated with change in plasma triglyceride concentration. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 12(11), pp.1284-1290.
- Mie, L.J., 2014. The effect of combination use of metformin and Valsartan on the waist circumference of patient with metabolic syndrome. Faculty of Medicine Gadjah Mada University, Yogyakarta.
- Müller-Fielitz, H., Landolt, J., Heidbreder, M., Werth, S., Vogt, F., Jöhren, O. & Raasch, W. (2012). Improved Insulin Sensitivity after Long-Term Treatment with AT 1 Blockers Is Not Associated with PPAR γ Target Gene Regulation. *Endocrinology*, 153(3), pp.1103-1115.
- Nambi, V., Hoogwerf, B.J. & Sprecher, D.L., 2002. A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia. *Cleveland Clinic Journal of Medicine*, 69(12), pp.985-989. Available at: <http://www.ccjm.org/cgi/doi/10.3949/ccjm.69.12.985>.
- National Institutes of Health 2000. *The practical guide: identification, evaluation and treatment of overweight and obesity in adults*, NIH Publication No. 00-4084.
- NewPK, E., 2015. Dietary patterns and changes in body mass index and waist circumference... - *PubMed* -

NCBI. [online] Ncbi.nlm.nih.gov. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/12791618>
[Accessed 1 Jan. 2015].

Nixon, R., Müller, E., Lowy, A. & Falvey, H. (2009). Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. *International Journal of Clinical Practice*, 63(5), pp.766-775.

Pan, W.H., Yeh, W.T., Weng, L.C., 2008. Epidemiology of metabolic syndrome in Asia. *Asia Pacific Journal of Clinical Nutrition*, 17:37-42.

Powers, A.C., 2005. Diabetes Mellitus. Dalam *Harrison's Principle of Internal Medicine*, 16th ed, Mc Graw Hill Medical Publishing Division, New York: 2152-80.

Sharma, A.M., Davidson, J., Koval, S., Lacourciere, Y., 2007. Telmisartan/ hydrochlorothiazide Valsartan/ hydrochlorothiazide in obese hypertensive patients with type 2 diabetes. *The SMOOTH Cardiovascular Diabetology*, 6:28.

Shiuchi, T., Iwai, M., Li, H., Wu, L., Min, L., Li, J., Okumura, M., Cui, T., Horiuchi, M., 2004. Angiotensin II receptor blocker Valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. *Hypertension* 43: 1003-1010.

Shuldiner, A., Yang, R. & Gong, D. (2001). Resistin, Obesity, and Insulin Resistance – The Emerging Role of the Adipocyte as an Endocrine Organ. *New England Journal of Medicine*, 345(18), pp.1345-1346.

Shuster, A., Patlas, M., Pinthus, J. & Mourtzakis, M. (2012). The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. *The British Journal of Radiology*, 85(1009), pp.1-10.

Sowers, J. (1998). Obesity and cardiovascular disease. *Clinical Chemistry*, [online] 44(8), pp.1821-1825. Available at:

<http://www.clinchem.org/content/44/8/1821.long>
[Accessed 30 Oct. 2014].

Steppan, C.M., Bailey, S.T., Bhat, S., 2001. The Hormone Resistin Links Obesity to Diabetes. *Nature* 409: 307-12.

Stevinkel, P., Pecoits-Filho, R., Lindholm, B., 2003. Leptin, Ghrelin, and Proinflammatory Cytokines: Compounds with Nutritional impact in Chronic Kidney Disease. *Advance in Renal Replacement Therapy* 10(4): 332-45.

Symonds, M., 2013. Brown Adipose Tissue Growth and Development. *Scientifica*, 2013, pp.1-14.

Tam, C., Lecoultre, V. & Ravussin, E., 2012. Brown Adipose Tissue: Mechanisms and Potential Therapeutic Targets. *Circulation*, 125(22), pp.2782-2791.

Tchernof, A., 2007. Visceral Adipocytes and the Metabolic Syndrome. *Nutrition Reviews*, 24: 29-36.

Teo., 2015. Lifestyle practices and obesity in Malaysian adolescents. - *PubMed - NCBI*. [online] Ncbi.nlm.nih.gov. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24886753> [Accessed 1 Jan. 2015].

The IDF Consensus Worldwide Definition of The Metabolic Syndrome. (2005). *Obesity and metabolism*, (3), p.47.

Uysal, K.T., Wiesbrock, S.M., Hotamisligil, G.S., 1998. Functional Analysis of Tumor Necrosis Factor (TNF) Receptors in TNF- α mediated Insulin Resistance in Genetic Obesity. *Endocrinology* 139: 4832-8.

Van der Zijl, N., Moors, C., Goossens, G., Hermans, M., Blaak, E., 2011. Valsartan improves (beta)-cell function and insulin sensitivity in subjects with impaired glucose metabolism: A randomized controlled trial. *Diabetes care* 34: 845-851.

- Vitale, C., 2005. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. *Cardiovascular Diabetology*, 4:6.
- Vollmer ., 2015. Effects of diet and sodium intake on blood pressure: subgroup analy... - PubMed - NCBI. [online] Ncbi.nlm.nih.gov. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11747380> [Accessed 1 Jan. 2015].
- Wajchenberg, B, 2000. Subcutaneous and Visceral Adipose Tissue Their Relation to the Metabolic Syndrome. *Endocrine Reviews*, 21(6): 697-38.
- Weisinger R., Begg D., Chen, N., Jois, M., Mathai, M., Sinclair, A., 2007. The problem of obesity: is there a role for antagonist of the renin-angiotensin system? *Asia Pacific Journal of Clinical Nutrition* 16 (Suppl 1): 359-367.
- Who.int, (2014). *WHO | Obesity and overweight*. [online] Available at: <http://www.who.int/mediacentre/factsheets/fs311/en/> [Accessed 22 Oct. 2014].
- Williamson, D., Kahn, H., Worthman, C., 1993. Precision of Recumbent Anthropometry. *American Journal of Human Biology*, 15:159-67.
- World Health Organization (WHO)., 1998, *Obesity: Preventing and Managing the Global Epidemic*, Report of a WHO Consultation on Obesity, Geneva.
- World Health Organization, 2008. Waist Circumference and Waist-Hip Ratio. *Report of a WHO Expert Consultation*. WHO. Geneva.
- Zappe, D., Sowers, J., Hsueh, W., Haffner, S., Deedwania, P., Fonseca, V., Keeling, L. & Sica, D. (2008). Metabolic and Antihypertensive Effects of Combined Angiotensin Receptor Blocker and Diuretic Therapy in Prediabetic Hypertensive Patients With the Cardiometabolic Syndrome. *The Journal of Clinical Hypertension*, 10(12), pp.894-903.